Efficacy of B-Cell–Targeted Therapy with Rituximab in Patients with Rheumatoid Arthritis

An open-label study indicated that selective depletion of B cells with the use of rituximab led to sustained clinical improvements for patients with rheumatoid arthritis. To confirm these observations, we conducted a randomized, double-blind, controlled study.